Search Site

Search form

Current Press Releases

All Releases
View Summary Vertex to Announce First Quarter 2015 Financial Results on April 29
Apr 9, 2015
PDF 6.8 KB
View Summary Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Mar 23, 2015
PDF 27.6 KB
View Summary Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO® (ivacaftor) for Children with Cystic Fibrosis Ages 2 to 5 who have Specific Mutations in the CFTR Gene
Mar 18, 2015
PDF 19.6 KB
View Summary Vertex to Present at Upcoming Investor Conferences
Feb 11, 2015
PDF 7.0 KB
View Summary Vertex Reports Full-Year and Fourth Quarter 2014 Financial Results and Provides Guidance for 2015
Jan 28, 2015
PDF 58.5 KB
View Summary Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis
Jan 11, 2015
PDF 30.2 KB
View Summary Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2014 Financial Results
Jan 6, 2015
PDF 7.2 KB
Showing 1-7 of 7 Page: 1